Key facts
- Impulse Biomedical’s last known valuation is $80K (Feb 2018).
- It has raised $170K.
- Notable investors include Launch Africa Ventures, Anza Capital, E Squared, Futuregrowth Asset Management, GSB Solution Space — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Impulse Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Impulse Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Impulse Biomedical
Developer of medical devices designed to offer assistance in the emergency treatment of anaphylaxis. The company provides proprietary adrenaline auto-injectors that can be customized for any patient, such as the needle length and dose, and primarily serves sectors that require medical devices for asthma and allergy treatments, enabling clinicians to avail of effective technologies to help save lives and reduce the impact of illnesses and chronic diseases on daily life.
- Sector
- Healthcare
- HQ
- Cape Town, South Africa
- Founded
- 2018
- Employees
- 13
- Website
- impulsebiomed.com/
- Ownership
- Privately Held (backing)
Impulse Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Impulse Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Impulse Biomedical in its N-PORT filings yet. We sweep new filings monthly.